The U.S. Internal Revenue Service issued a $32,350.20 penalty to Dr Reddy’s Laboratories, Inc., the wholly‑owned U.S. subsidiary, on October 2, 2026 after a misclassification of the fiscal year reference during tax payment. According to the company’s filing, the fine is a one‑off and not expected to dent its financials.
The NSE price slipped 2.51%, closing at ₹1,202 on October 1, 2026. That was a sharper fall than the 1.2% dip seen in the broader pharma index that day, hinting at a localized reaction to the penalty news.
In a parallel development, the U.S. Food and Drug Administration completed a records assessment at Dr Reddy’s Mexico facility between July 17 and September 8, 2026, issuing Form FDA 2953 with two observations. The company said it will respond within the stipulated timeline, but no market‑moving guidance has been issued yet.
The penalty, while small in absolute terms, underscores regulatory scrutiny for foreign‑listed U.S. entities. Analysts note that other pharma names faced similar fines last year, but most saw muted price swings – under 1%.
Looking ahead, Dr Reddy’s will report its first‑quarter results on October 31. Investors will be watching for any commentary on tax compliance costs and the FDA observations, as these could influence the company’s margin outlook.